State of the art in the delivery of photosensitizers for photodynamic therapy

Konan, Yvette Niamien; Gurny, Robert; Allémann, Éric

doi:10.1016/s1011-1344(01)00267-6

Cited by 847 publications

(659 citation statements)

References 119 publications

Supporting

Mentioning

594

Contrasting

Unclassified

Order By: Relevance

“…Besides their effectiveness in PDT treatments, poor selectivity for diseased tissues, high dose, extended retention in the host organism, and low wavelength activation (630 nm) were the main drawbacks (7,14). These drawbacks stimulated the development of new PSs showing fast elimination from the body, fewer side effects, and a higher absorption peak (650-800 nm) (6,7,15).…”

Section: Photosensitizer Liposome Formulationsmentioning

confidence: 99%

“…The drug delivery system is expected to incorporate high amounts of the PS without loss or alteration of its activity, to selectively accumulate the PS in the diseased tissue, to deliver therapeutic amounts of PS to the target site, to protect the PS from degradation and from premature clearance, to minimize drug leakage during transit to target, and to facilitate PS interaction with cells; moreover, the delivery system must be biodegradable and should induce little or no immunogenicity (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy

Muehlmann

Joanitti

Silva

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Photosensitizer Liposome Formulationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy

Muehlmann

Joanitti

Silva

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

“…Another second generation PS [16] is aminolevulinic acid (ALA) which was approved for the treatment of basal cell carcinomas, Paget's disease, squamous cell carcinomas, T-cell lymphomas and other cancer types such as lung, bladder, oral cavity, esophagus and brain tumors. ALA is particularly effective in dermatology for treating neoplastic cutaneous tissues [4].…”

Section: Introductionmentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

“…[1] In comparison with microcapsules [2] the diameters of which range between 1and 800 mm, nanocapsulesa re particles [3] having diameters smaller than 1 mm. Due to their nanoscale dimensions, nanocapsules have the capability to enhanceb ioavailability, improvec ontrolled release performance and enable the precise targeted delivery of drugs, food, and other bioactive compounds.…”

Section: Introductionmentioning

confidence: 99%

pH‐Responsive Porous Nanocapsules for Controlled Release

Song

Wei

et al. 2017

Chemistry A European J

View full text Add to dashboard Cite

In this work pH-responsive porous nanocapsules have been successfully prepared from at ernary graft copolymer,p oly(glycidyl methacrylate)-g-[poly(2-cinnamoyloxyethyl methacrylate)-r-poly(ethyleneg lycol) methyl ether-r-poly(2-diethylaminoethyl methacrylate)] or PGMA-g-(PCEMA-r-MPEG-r-PDEAEMA).T he graft copolymersw eref abricated by grafting three types of polymer chains onto the backbone polymer by using click chemistry.T hese ternary copolymers underwents elf-assembly to form vesicles in aD MF/water solvent mixture. While the MPEG chains served as the corona and stabilized the vesicles, the vesicle wall was composed of ad ominant PCEMA continuous phase that was interspersed by PDEAEMA domains. After photo-cross-linking, the PDEAEMA domains were embedded in the structurally locked PCEMA wall. By decreasing the pH of the externals olution, we were able to trigger the release of encapsulated pyrene due to the capsule wall becoming porousa saresult of the PDEAEMA chains bearing positivelyc harged amine groups stretching into the water.W hile these pH-responsive porousn anocapsulese xhibited potential applications in drug delivery,d etection and catalysis, the strategy reported in this contribution also represented an ew paradigm for the design and preparation of other novel stimuli-responsive porousnanocapsules.

show abstract

State of the art in the delivery of photosensitizers for photodynamic therapy

Cited by 847 publications

References 119 publications

Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy

Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy

Nanodrug applications in photodynamic therapy

pH‐Responsive Porous Nanocapsules for Controlled Release

Contact Info

Product

Resources

About